


1644
FFW

I hereby certify that this communication is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 14, 2005 Signature: 
(Sharon M. Stinich)

Docket No.: 01017/40451C
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Brockhaus et al.

Application No.: 08/444,791

Filed: May 19, 1995

For: HUMAN TNF RECEPTOR



Confirmation No.: 5613

Art Unit: 1644

Examiner: Ronald B. Schwadron

**AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This amendment is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed March 4, 2005. This response is timely filed.

Amendments to the Sequence Listing begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 9 of this paper.

04/06/2005 K00UNITS 000000002 132855
01 FC:1202 200.00 DA

REMARKS


In the Notice to Comply, the Examiner stated the definition of "Xaa" in SEQ ID NOS: 5, 10, 11 and 14 should read "unknown amino acid," and the sequences set out as SEQ ID NOS: 18, 20, 22 and 24 should be presented in 5' to 3' direction. The substitute sequence listing submitted herewith correct these informalities and does not add new matter to the application. Also enclosed is a statement confirming that the content of the paper and computer readable copies of the sequence listing submitted herewith are the same and do not add new matter.

The Examiner also stated that all the sequences recited in the claims should be identified by the appropriate sequence identification number. In the foregoing amendment, claims 127, 128, 135, 136, 142 and 143 were amended to add the appropriate sequence identification numbers. These amendments do not add new matter to the application. The amendments to the claims were made solely to put the claims in better compliance with the sequence rules set out in 37 C.F.R. §§ 1.821-1.825.

No fee is believed to be due with the filing of this paper. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/40451C. A duplicate copy of this paper is enclosed.

Dated: March 14, 2005

Respectfully submitted,

By, 
Sharon M. Sintich
Registration No.: 48,484
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant